Breast Cancer
Breast-conserving therapy may be viable option for multiple ipsilateral breast cancer
SAN ANTONIO — Lumpectomy followed by radiation therapy resulted in low rates of local recurrence at 5 years among women with multiple ipsilateral breast cancer, according to phase 2 study results.
Low-dose tamoxifen confers sustained reduction in recurrence risk in noninvasive breast cancer
SAN ANTONIO — Use of low-dose tamoxifen conferred a sustained reduction in risk for recurrence among women with noninvasive breast cancer, according to updated results from the randomized, phase 3 TAM-01 trial.
Top in hem/onc: Cumulative stress and cancer risk; thromboembolism biomarkers in COVID-19
High allostatic load indicating lifelong stress was linked to a 106% increased risk for cancer-associated death among young Black individuals and a 95% increased risk among young white individuals, according to a recent study.
Commercial insurance rates for breast reconstruction vary greatly across US
The commercial insurance costs for breast reconstruction vary greatly across the United States, with less competitive markets and large, for-profit and nonsafety-net hospitals seeing the highest rates.
NCI director announces breast cancer diagnosis, says prognosis ‘very favorable’
Monica M. Bertagnolli, MD, FACS, FASCO, director of the NCI, announced today that she has been diagnosed with early-stage hormone receptor-positive, HER2-negative breast cancer.
Highlights from SABCS 2022
In this episode of Meeting Mic, we bring you the highlights and insights from the SABCS 2022, as well as Healio’s top headlines from the meeting.
Tamoxifen treatment for breast cancer may increase endometrial disease, cancer risks
Tamoxifen use in the treatment of breast cancer was associated with greater risks for endometrial cancer, hyperplasia and polyps, as well as other uterine cancers among premenopausal women in Korea, according to study data.
Survey: 20% of women with high deductible would forgo testing after abnormal mammogram
One in five women with high-deductible health insurance plans who had an abnormal screening mammogram would opt out of follow-up testing, according to survey results presented at the Radiological Society of North America annual meeting.
Capivasertib regimen represents potential new treatment option for advanced breast cancer
SAN ANTONIO — The addition of capivasertib to fulvestrant significantly extended PFS among patients with hormone receptor-positive, HER2-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.
Camizestrant extends PFS for postmenopausal women with advanced breast cancer
SAN ANTONIO — Camizestrant significantly prolonged PFS compared with fulvestrant among postmenopausal women with advanced ER-positive, HER2-negative breast cancer, according to study results.